LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Platform Offers Patients Ultrafast Genetic Diagnosis

By LabMedica International staff writers
Posted on 01 Jan 2024
Print article
Image: The Genomtec ID mobile platform for genetic diagnostics (Photo courtesy of Genomtec SA)
Image: The Genomtec ID mobile platform for genetic diagnostics (Photo courtesy of Genomtec SA)

Molecular diagnostics traditionally requires knowledge of handling complex equipment and sample preparation. Now, a simple mobile platform for genetic diagnostics that is currently under development can be handled by healthcare professionals without any laboratory training.

Genomtec SA (Wrocław, Poland) is developing its flagship technological solution named Genomtec ID platform which will offer patients ultrafast mobile genetic diagnosis. The Genomtec ID platform is designed to facilitate diagnostic procedures on-site, including locations like public clinics, consulting rooms, hospitals, pharmacies, and emergency wards, eliminating the necessity for complex, time-consuming lab operations. The technology at the heart of Genomtec ID is the patented Streamlined Nucleic Acid Amplification Technology (SNAAT). This innovation ensures precise pathogen identification within 15 minutes, making it a rapid diagnostic solution. The Genomtec ID system combines the LAMP (loop-mediated isothermal amplification) method with microfluidics and a contactless photonic heating system. This integration allows for simultaneous isolation, purification, concentration, amplification, and detection of specific DNA or RNA fragments of pathogens, significantly speeding up the process while ensuring accuracy on par with or superior to conventional lab-based PCR methods.

One of the standout features of the SNAAT method is its capability for multiplexing, allowing for the simultaneous detection of multiple diagnostic targets on a microfluidic card. This means a single test can identify up to five pathogens at once. The use of a passive microfluidic card, devoid of embedded electronics or electric parts, for nucleic acid isolation, purification, and concentration, not only enhances the detection threshold for target nucleic acids but also reduces the manufacturing costs of disposable reaction cards. The robust diagnostic parameters offered by SNAAT, including sensitivity, specificity, and repeatability, are largely due to its resistance to common inhibitors found in biological samples like blood or drugs. This resistance makes SNAAT an innovative and reliable technology for point-of-care care testing (POCT), promising a new era of convenient and rapid diagnostics accessible to a broader range of healthcare settings.

Related Links:
Genomtec SA

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.